A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS

Denise C. Hsu, Kimberly F. Faldetta, Luxin Pei, Virginia Sheikh, Netanya S. Utay, Gregg Roby, Adam Rupert, Anthony S. Fauci, Irini Sereti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

Original languageEnglish (US)
Pages (from-to)258-261
Number of pages4
JournalClinical Infectious Diseases
Volume62
Issue number2
DOIs
StatePublished - Jan 15 2016

Fingerprint

Immune Reconstitution Inflammatory Syndrome
Adrenal Cortex Hormones
Therapeutics
Tumor Necrosis Factor-alpha
Clinical Trials
Infliximab

Keywords

  • immune reconstitution inflammatory syndrome
  • infliximab
  • mycobacterial infection

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Hsu, D. C., Faldetta, K. F., Pei, L., Sheikh, V., Utay, N. S., Roby, G., ... Sereti, I. (2016). A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS. Clinical Infectious Diseases, 62(2), 258-261. https://doi.org/10.1093/cid/civ841

A Paradoxical Treatment for a Paradoxical Condition : Infliximab Use in Three Cases of Mycobacterial IRIS. / Hsu, Denise C.; Faldetta, Kimberly F.; Pei, Luxin; Sheikh, Virginia; Utay, Netanya S.; Roby, Gregg; Rupert, Adam; Fauci, Anthony S.; Sereti, Irini.

In: Clinical Infectious Diseases, Vol. 62, No. 2, 15.01.2016, p. 258-261.

Research output: Contribution to journalArticle

Hsu, DC, Faldetta, KF, Pei, L, Sheikh, V, Utay, NS, Roby, G, Rupert, A, Fauci, AS & Sereti, I 2016, 'A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS', Clinical Infectious Diseases, vol. 62, no. 2, pp. 258-261. https://doi.org/10.1093/cid/civ841
Hsu, Denise C. ; Faldetta, Kimberly F. ; Pei, Luxin ; Sheikh, Virginia ; Utay, Netanya S. ; Roby, Gregg ; Rupert, Adam ; Fauci, Anthony S. ; Sereti, Irini. / A Paradoxical Treatment for a Paradoxical Condition : Infliximab Use in Three Cases of Mycobacterial IRIS. In: Clinical Infectious Diseases. 2016 ; Vol. 62, No. 2. pp. 258-261.
@article{7d47e1826fbf413490da667ce88ea0b6,
title = "A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS",
abstract = "The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.",
keywords = "immune reconstitution inflammatory syndrome, infliximab, mycobacterial infection",
author = "Hsu, {Denise C.} and Faldetta, {Kimberly F.} and Luxin Pei and Virginia Sheikh and Utay, {Netanya S.} and Gregg Roby and Adam Rupert and Fauci, {Anthony S.} and Irini Sereti",
year = "2016",
month = "1",
day = "15",
doi = "10.1093/cid/civ841",
language = "English (US)",
volume = "62",
pages = "258--261",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A Paradoxical Treatment for a Paradoxical Condition

T2 - Infliximab Use in Three Cases of Mycobacterial IRIS

AU - Hsu, Denise C.

AU - Faldetta, Kimberly F.

AU - Pei, Luxin

AU - Sheikh, Virginia

AU - Utay, Netanya S.

AU - Roby, Gregg

AU - Rupert, Adam

AU - Fauci, Anthony S.

AU - Sereti, Irini

PY - 2016/1/15

Y1 - 2016/1/15

N2 - The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

AB - The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

KW - immune reconstitution inflammatory syndrome

KW - infliximab

KW - mycobacterial infection

UR - http://www.scopus.com/inward/record.url?scp=84960172014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960172014&partnerID=8YFLogxK

U2 - 10.1093/cid/civ841

DO - 10.1093/cid/civ841

M3 - Article

C2 - 26394669

AN - SCOPUS:84960172014

VL - 62

SP - 258

EP - 261

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -